Eli Lilly and Company (LLY)

295.19
NYSE
Prev Close 301.40
Day Low/High 294.03 / 302.60
52 Wk Low/High 193.11 / 314.00
Exchange NYSE
Shares Outstanding 950.16B
Market Cap 286.38B
P/E Ratio 33.79
Div & Yield N.A. (N.A)
In a Sick Market, Can Pharmas Help?

In a Sick Market, Can Pharmas Help?

Let's check the charts of three drug names, Merck, Eli Lilly and Bristol-Myers Squibb.

Eli Lilly's Charts Look a Bit Frail

Eli Lilly's Charts Look a Bit Frail

LLY is looking shaky, despite fundamental improvements from its weight-loss drug tirzepatide.

Premarket Movers

Upside - +74% (enters strategic agreement with Immune Therapeutics for rights to low dose naltrexone) - +18% (earnings, guidance) - +16% (earnings, guidance) - +14% (earnings) - +11% (earnings, guidance) - +10% (earnings, guidance) - +9.1% (highligh...

The Good, the Bad and the Ugly, Trading Meta Platforms, What's Down Teladoc?

The Good, the Bad and the Ugly, Trading Meta Platforms, What's Down Teladoc?

Wednesday's session was dominated by traders, algorithmic traders for sure, but traders nonetheless. The PMs mostly sat on their hands.

I'm Prescribing a New Approach Toward Eli Lilly as It Loses Upward Momentum

I'm Prescribing a New Approach Toward Eli Lilly as It Loses Upward Momentum

A couple bearish divergences indicate that the pace of the advance in the giant drugmaker's shares is slowing.

7 Best Buys in Biotech and Drug Development

7 Best Buys in Biotech and Drug Development

Recently poor sector performance is creating opportunity for long-term investors.

Raising Stops on Eli Lilly as the Charts Weaken

Raising Stops on Eli Lilly as the Charts Weaken

Here's what I recommend.

Melting Candles, Meta, Spotify, Tech-Ageddon, Jobs Mess, Healthcare Hot Tickets

Melting Candles, Meta, Spotify, Tech-Ageddon, Jobs Mess, Healthcare Hot Tickets

Just a week ago Jerome Powell referred to the labor market as 'strong.' Now, economists, traders, investors, and the public are just not quite sure what to expect Friday.

Eli Lilly Raised at DZ Bank

My 2022 Technical Outlook: Beware of the Treacherous Road Ahead

My 2022 Technical Outlook: Beware of the Treacherous Road Ahead

Unless you are a great stock picker and timer, a strategy of taking profits into available strength the next two months is key.

Faux Rally, Worrisome Words, Omicron Overhang, Microsoft CEO's Stock Sales

Faux Rally, Worrisome Words, Omicron Overhang, Microsoft CEO's Stock Sales

Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.

Eli Lilly Rated at BMO

October Rebound, Pricing In the Past, Tesla Hertz So Good, Space, Facebook Q&A

October Rebound, Pricing In the Past, Tesla Hertz So Good, Space, Facebook Q&A

Markets are pricing in some fiscal policy, but it's not what a lot of pundits think.

What to Watch Next Week

Next Week (Selected Macro) Monday   AM: PM:   Tuesday   AM: , , , , , PM: , , ,   Wednesday   AM: , , , PM: , ,   Thursday   AM: PM: , ,   Friday   AM: , PM: none Next Week (Selected Macro)   Monday: Dallas Fed Manufacturing Index   Tuesday: Case-Sh...

Eli Lilly Raised to Buy at Citi

While This Market Action Makes for Some Tough Trading, It's Nothing Unusual

While This Market Action Makes for Some Tough Trading, It's Nothing Unusual

Pockets of speculative trading are narrower, but the appetite for action has not disappeared.

Stall Speed? Jobs Gut Punch, Taiwan Worries, Mu Variant, Trading AbbVie

Stall Speed? Jobs Gut Punch, Taiwan Worries, Mu Variant, Trading AbbVie

What if areas of expected growth in labor market demand moving forward do not materialize?

Pfizer's Charts Suggest a Strong Rally Ahead

Pfizer's Charts Suggest a Strong Rally Ahead

Here are our latest price targets.

Jim Cramer: The Drug Cos. Are at Full Strength

Jim Cramer: The Drug Cos. Are at Full Strength

We're seeing a group move in pharma right now, so let's sort it out, pill by pill.

Market on Eggshells, Masking Up, ISM, Pfizer and Moderna Just Getting Started

Market on Eggshells, Masking Up, ISM, Pfizer and Moderna Just Getting Started

Doesn't the Fed now have to taper asset purchases simply to avoid becoming an even greater force in these markets?

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.

Eli Lilly Is Going Strong: Here's How to Play It

Eli Lilly Is Going Strong: Here's How to Play It

Let's check out the LLY charts amid FDA approval of the company's Alzheimer's drug.

Jim Cramer: It's a Jailbreak and the Stocks Are Busting Out

Jim Cramer: It's a Jailbreak and the Stocks Are Busting Out

This market is moving in so many areas that you have to marvel at how it's even possible -- even if the Russell Rebalancing could change all that on Friday.

Biogen's Japanese Partner on Alzheimer's Drug Set for Gains

Biogen's Japanese Partner on Alzheimer's Drug Set for Gains

Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.

Jim Cramer: Here's What Can Go Higher

Jim Cramer: Here's What Can Go Higher

Let's look at the companies that can go up, and the ones that can't.

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'

My Beautiful Balloon, Unmasking the Market, Crypto Risk, Preparing for Powell

My Beautiful Balloon, Unmasking the Market, Crypto Risk, Preparing for Powell

With the economy apparently growing robustly, the Fed has to watch how the president's plans play out in terms of the size and scope of deficit spending.

My Favorite Day of the Month: Options Expiration Day

My Favorite Day of the Month: Options Expiration Day

I have become a huge devotee of this simple option strategy. Here are two recent examples from this week.

Jim Cramer: We've Got a Boom ... and a Bust

Jim Cramer: We've Got a Boom ... and a Bust

Let's look at this impossible move on the market -- and why health care could be coming off life support.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Let's review the charts and indicators.